Related Experiment Video
Updated: Jan 28, 2026

Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging
Published on: December 4, 2016
An Overview of Small-Molecule Agents for the Treatment of Dermatomyositis
Xuechun Liu1,2, Ziwen Feng1,2, Chunchen Che1,2
1State Key Laboratory of Natural Medicines and Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
Abstract:
Dermatomyositis (DM) is a multifaceted autoimmune disorder arising from immune dysregulation and pathogenic (bacterial/viral) infections. The current therapeutic framework predominantly employs glucocorticoids, monoclonal antibodies, and immunosuppressive agents as first-line treatments. Nevertheless, there remains a critical need to develop novel targeted therapies that offer enhanced efficacy and reduced toxicity. This review comprehensively analyzes recent advances in small-molecule drug discovery for DM. Analyzing the Structure-Activity Relationship (SAR) of small molecule inhibitors and integrating the latest patents, this review combines both molecular design and clinical evidence with therapeutic strategies to point the way to the development of highly selective small molecules that target DM, a complex autoimmune disease, and ultimately contribute to the improvement of patients' prognosis and quality of life.
Related Concept Videos
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Molecules and Compounds
Subviral Agents

